IDEXX Laboratories, Inc. IDXX

Key data

The business

IDEXX sells diagnostics to veterinarians. A clinic buys an analyzer that sits on the counter, a chemistry or hematology machine, sometimes a full in-house lab, and from then on buys the slides, reagents and rapid test kits that only run on IDEXX gear. What the analyzer can't do in-house gets shipped to an IDEXX reference lab. Together that is the Companion Animal Group, and it is essentially the whole company; Water testing and livestock diagnostics are rounding error by comparison. The moat is the installed base: once a machine is placed and a clinic's workflow is built around it, switching means retraining staff and requalifying tests, so the recurring revenue behind each box compounds for years. Growth comes from three levers stacked: place more machines, get each clinic to run more tests per visit, and raise price. The thing a vet actually holds is a SNAP test or a slide that costs a few dollars and gets reordered every week, which is the entire economic model in one object.

The numbers

The shape is steady growth bent slightly upward in the most recent quarter.

Q2 2026 is the inflection: revenue growth stepped up to 9.7% year over year and diluted EPS to 17.6%, the widest gap between the two in the set, which is operating leverage and the buyback working together. Gross margin reached 64.0% from 62.6% a year earlier, driven by price realization and premium instrument mix, not volume heroics.

Across five years revenue compounded about 7.6% a year and EPS about 11%, the gap being margin expansion and a share count shrinking roughly 2% annually. First-half 2026 revenue is up 11.8% and net income 14.9%, so the rate is holding, not fading. The variant here is narrow: the market pays a premium multiple sitting near the low end of its own twelve-year range for a franchise growing earnings mid-teens with a 72% return on equity, yet the stock sits near its 52-week low. What the market disbelieves is the durability of price-led growth; the print that settles it is CAG organic recurring revenue, and whether it stays high-single-digits without a volume tailwind.

One table shows why the whole argument is really about one segment.

Management

Insiders only sell. Zero buys in twelve months against 23 sales worth $22.5M, the largest a cluster from CEO Jonathan Mazelsky in February 2026, about $6.2M across three same-day trades; plan status is not disclosed in the filings, so read it as neither reassuring nor alarming. The louder capital signal is the buyback: IDEXX spent $1.2B on its own stock last year, some of it well above today's price, which is the recurring sin of a company that repurchases into strength and pauses into weakness. More encouraging, long-term debt has been cut from over $900M in 2020 to $450M, so the balance sheet delevered while the buyback ran. Management has beaten the consensus EPS number eight quarters running, including every one of the last four, which tells you they guide conservatively.

How it fails or surprises you

US pet-visit volume turns structurally negative. Clinical visit counts have been soft across the industry. If they stay negative, CAG recurring growth leans entirely on price, and vets push back on price eventually. The print that reveals it first is CAG organic recurring revenue with US same-store visits in the Q3 release; price doing all the lifting while volume shrinks keeps the multiple compressing.

The market disbelief itself. The fact the read explains least: accelerating earnings, a falling stock. If the market is right and not mispricing, growth is about to slow and the FY2026 guide will say so. Watch the next guidance revision against the eight-quarter beat streak; a maintained or cut guide despite the Q2 beat would confirm the sellers, not the tape.

Price, placements and new panels re-rate it (right tail). If instrument placements and net price hold at the Q2 pace and advanced panels attach, EPS compounds mid-teens while the multiple lifts off a 33rd-percentile EV/EBITDA. The market pays for a slowdown that the placement data would refute. The print: instrument placements and net price realization in Q3, both of which the company breaks out.

Closing thoughts

The market already prices most of what makes IDEXX good, the installed base, the recurring model, the moat, and the argument is over what multiple that earns. On the other side are sellers betting US visit softness caps growth and that 38 times cannot hold as the last cheap-money re-rating unwinds. My read is that recurring mix, price realization and a steady buyback deliver mid-teens EPS growth with the multiple already a third of the way down from its own ceiling, so the reward for the model working is both earnings and re-rating. The fatter tail is modestly up, because the left tail, a structural decline in pet-visit volume, is slow and visible quarter by quarter, and a delevered balance sheet with a 72% return on equity survives it either way.

The bet is still that vets keep installing IDEXX machines and buying the tests that run on them, and that pet owners keep showing up. What breaks it is US visit volume turning structurally negative while price loses its grip. The one pair that tells you first is CAG organic recurring revenue against US same-store visit counts in the next print: if recurring growth slips toward the volume line with no price offset, the story is breaking, and no multiple discount will have been cheap enough.